Glytec’s electronic glycemic management system uses data to determine the patient’s insulin levels
Interview with Steven Loeb and Bambi Francisco John Downey, Chief Commercial Officer at Glytec, a provider of electronic glycemic management systems (eGMS) that uses real-time data to ensure that hospitals are giving patients the right amount of insulin. The companys eGMS, called Glucommander, uses real-time and historical data to personalize insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs.
Glytec was founded in 2006 and has raised $ 65 million in funding, including a recent round of $ 21 million.
For these digital health podcasts, our goal is to understand these three overarching questions as well: How do we empower consumers? Are we creating a productivity that also enables us to reduce overall economic costs? How is this advancement changing the role of the doctor?
Highlights from the interview:
- Glytec is currently concentrating on the inpatient area and offers two products: one for IV and one for SubQ insulin dosing. The software uses an algorithm that takes into account, among other things, the condition of each patient and their insulin tolerance in order to correctly determine the correct insulin level.
- Approximately 40% of the patients who are admitted to the hospital have high blood sugar and 25% of these patients will have new symptoms; They may be a diabetic who doesn’t know they have it, but someone who’s having a heart attack or stroke could also have high blood sugar levels.
- In addition to Glucommander, the company has a product called GlucoSurveillance, which uses inputs from multiple hospital systems to analyze a patient’s blood glucose levels and determine if intervention is needed. In hospitals with undiagnosed diabetes, GlucoSurveillance can determine who is in need of insulin before it gets out of hand.
- Glytec is sometimes used as a diagnostic tool for patients who do not know they have diabetes. The company has FDA approval for its ambulatory outpatient product and could potentially expand into these new markets as they emerge. Through partnerships, there are opportunities for Glytec to get to the point where it takes input into the system and is used in a diagnostic way to determine who should be receiving insulin.
- Companies such as Virta and Livongo, which also operate diabetes management, are potential partners for Glytec. The company believes its technology can be coupled with services and that it can be more of a community health company selling to payers and employers. The company had some early-stage agreements with Livongo to use its technology to coach patients with diabetes.
- There are 6,000 hospitals in the US, 10% of which use an eGMS. Insulin was discovered 100 years ago this month, so most hospitals’ approach to insulin hasn’t changed in a century. The fact that 90% of hospitals still have a unified approach is a great opportunity for the company.
- There are five factors the company considers when pricing: the number of beds in a facility, the number of annual discharges, the expected ROI, the number of locations to contract, and what the competitors are in the market. All of these things are used to determine the annual fee the hospital will pay for unlimited use.
- The company is open to a values-based model, but hospitals do not want to enter into a risk-sharing agreement due to the unpredictability. To get around this, Glytec said hospitals wouldn’t have to pay until the following fiscal year so that hospitals can budget for the difference.
- As a result of using Glytec, hospitals see a 90% reduction in severe hypoglycemia and hyperglycemia, resulting in fewer infections, improved wound healing and fewer readmissions. The solution can cut length of stay by 2.7 days, opening hospital beds and admitting more patients, and these are revenue-generating patients for the hospital as they are paid on a case-by-case basis.
This podcast is sponsored by BetterHelp and VatorNews listeners get a 10% discount for the first month at BetterHelp.com/Vator. This podcast is also provided by Octave, your mental health and emotional wellbeing partner. Learn more at FindOctave.com. Also thanks to NeuroFlow, which works with hundreds of health organizations to provide world-class technology and services for the effective integration of behavioral health.
Subscribe to our podcasts to receive our interviews and shows as soon as they are released!